Effectiveness on Sino-Nasal Symptoms Of Mepolizumab 300

Conditions

• Sinus Disease
• EGPA - Eosinophilic Granulomatosis With Polyangiitis
• Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

Interventions

• DRUG: Mepolizumab 300 mg

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS